ABSTRACT
Genome-wide association studies (GWAS) have been performed to identify host genetic factors for a range of phenotypes, including for infectious diseases. The use of population-based common controls from biobanks and extensive consortiums is a valuable resource to increase sample sizes in the identification of associated loci with minimal additional expense. Non-differential misclassification of the outcome has been reported when the controls are not well-characterized, which often attenuates the true effect size. However, for infectious diseases the comparison of cases to population-based common controls regardless of pathogen exposure can also result in selection bias. Through simulated comparisons of pathogen exposed cases and population-based common controls, we demonstrate that not accounting for pathogen exposure can result in biased effect estimates and spurious genome-wide significant signals. Further, the observed association can be distorted depending upon strength of the association between a locus and pathogen exposure and the prevalence of pathogen exposure. We also used a real data example from the hepatitis C virus (HCV) genetic consortium comparing HCV spontaneous clearance to persistent infection with both well characterized controls, and population-based common controls from the UK Biobank. We find biased effect estimates for known HCV clearance-associated loci and potentially spurious HCV clearance-associations. These findings suggest that the choice of controls is especially important for infectious diseases or outcomes that are conditional upon environmental exposures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study: 2R01AI148049 along with a COVID-19 supplement under the same grant number (D.L.T, P.D., G.L.W) and Burroughs-Wellcome Fund, MD-GEM training grant (D.D.). G.L.W. was additionally supported by the National Human Genome Research Institute (NHGRI) grant R35HG011944.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access and use of data from the UK Biobank was approved using application number 17712. Consent was obtained for genotyping as approved by the governing IRB and DNA provided to Johns Hopkins School of Medicine without identifiers, as described previously (doi: 10.1053/j.gastro.2018.12.014, 10.7326/0003-4819-158-4-201302190-00003).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.